IMR Press / CEOG / Volume 40 / Issue 1 / pii/1630388031983-682885421

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Origianal Research
Loss of heterozygosity in the fragile histidine triad (FHIT) locus and expression analysis of FHIT protein in patients with breast disorders
Show Less
1 Clinical Pathology, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais
2 Department of Clinical Analyses, Toxicological and Bromatological, Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP), Ribeirão Preto, São Paulo
3 Discipline of Special Pathology, Department of Biological Sciences, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais
4 Discipline of Gynecology and Obstetrics, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais
5 Discipline of Microbiology, Instituto Federal de Educação, Ciência e Tecnologia do Triângulo Mineiro (IFTM), Uberaba, Minas Gerais
6 Discipline of Gynecology and Obstetrics, Oncologycal Research Institute (IPON), Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais
7 Discipline of Molecular Biology, Department of Biochemistry, Pharmacology and Physiology, Instituto de Ciências Biológicas e Naturais, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, Minas Gerais (Brazil)
Clin. Exp. Obstet. Gynecol. 2013, 40(1), 89–94;
Published: 10 March 2013
Abstract

Purpose of investigation: The fragile histidine triad (FHIT) gene is a tumor suppressor frequently inactivated in various types of tumors. The authors evaluated the occurrence of loss of heterozygosity (LOH) in the FHIT locus and FHIT protein changes in breast tissue. Materials and Methods: Blood and breast tissue samples were obtained from 35 women with mammary disorders. The occurrence of LOH in FHIT locus was assayed by polymerase chain reaction (PCR), and the results obtained from blood and breast tissues from each patient were compared. FHIT protein expression was evaluated by immunohistochemistry. Results: LOH in the FHIT gene occurred in 48.6% (17/35) of patients with mammary disorder. Among patients with malignant breast disorders, 59.1% (13/22) presented LOH in the FHIT gene in comparison with patients with benign breast lumps, in which the LOH was observed in 30.8% (4/13) of women, suggesting that changes in this gene occur prior to the process of mammary carcinogenesis. The changes in the locus of the FHIT gene occur with greater frequency in the coded region of the gene, principally near exons 5 and 8, where the FRA3B site and the histidine triad respectively are found. Changes in FHIT did not modify protein expression. The association between menopause and LOH in the FHIT gene was evident. Conclusions: LOH in the FHIT gene may be related to menopause in women with breast disorders.
Keywords
Breast neoplasm
Loss of heterozygosity
Fragile histidine triad protein [supplementary concept]
Tumor Suppressor Gene
Menopause
Share
Back to top